HIV治療薬の世界市場の世界市場2015-2019...市場調査レポートについてご紹介

【英文タイトル】Global HIV Drugs Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 06: Market segmentation by drug class

PART 07: Global multi-class combination products market
Global multi-class combination products market

PART 08: Global nucleoside reverse transcriptase inhibitors market
Global nucleoside reverse transcriptase inhibitors market

PART 09: Global non-nucleoside reverse transcriptase inhibitors market
Global non-nucleoside reverse transcriptase inhibitors market

PART 10: Global protease inhibitors market
Global protease inhibitors market

PART 11: Global fusion inhibitors market
Global fusion inhibitors market

PART 12: Global entry inhibitors — CCR5 co-receptor antagonist market
Global entry inhibitors — CCR5 co-receptor antagonist market

PART 13: Global HIV integrase strand transfer inhibitors market
Global HIV integrase strand transfer inhibitors market

PART 14: Geographical segmentation
Global HIV drugs market segmentation by geography

PART 15: Market drivers
Increased funding
Rise in patient population
Unmet medical needs
Initiatives by governments

PART 16: Impact of drivers

PART 17: Market challenges
Expiry of patents
Associated social stigma
Side effects of drugs
Complications in disease diagnosis

PART 18: Impact of drivers and challenges

PART 19: Market trends
Rise in public awareness
Strategic alliances
Novel approaches

PART 20: US Government: Funding for HIV

PART 21: Vendor landscape
Competitive scenario
Market share analysis
Other prominent vendors

PART 22: Key vendor analysis
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck

PART 23: Appendix
List of abbreviations

PART 24: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Global HIV drugs market 2014-2019 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Global HIV drugs market segmentation by drug class 2014
Exhibit 05: Global HIV drugs market segmentation by drug class 2014-2019 ($ millions)
Exhibit 06: Global multi-class combination products market 2014-2019 ($ millions)
Exhibit 07: Global nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
Exhibit 08: Global non-nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
Exhibit 09: Global protease inhibitors market 2014-2019 ($ millions)
Exhibit 10: Global fusion inhibitors market 2014-2019 ($ millions)
Exhibit 11: Global entry inhibitors — CCR5 co-receptor antagonist market 2014-2019 ($ millions)
Exhibit 12: Global HIV integrase strand transfer inhibitors market 2014-2019 ($ millions)
Exhibit 13: Global HIV drugs market segmentation by geography 2014
Exhibit 14: Global HIV drugs market segmentation by geography 2014-2019 ($ millions)
Exhibit 15: HIV drugs market in Americas 2014-2019 ($ millions)
Exhibit 16: HIV drugs market in EMEA 2014-2019 ($ millions)
Exhibit 17: HIV drugs market in APAC 2014-2019 ($ millions)
Exhibit 18: Assistance from donor governments for HIV treatment 2013
Exhibit 19: Global HIV statistics 2014
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22: Funding by the US government for HIV 2010-2016 ($ billions)
Exhibit 23: Funding by the US government for domestic treatment and care of HIV 2010-2016 ($ billions)
Exhibit 24: Bristol-Myers Squibb: Revenue of Reyataz 2012-2014 ($ billions)
Exhibit 25: Bristol-Myers Squibb: Revenue of Sustiva 2012-2014 ($ billions)
Exhibit 26: Gilead Sciences: Revenue of Stribild 2012-2014 ($ millions)
Exhibit 27: Gilead Sciences: Revenue of Truvada 2012-2014 ($ billions)
Exhibit 28: Gilead Sciences: Revenue of Emtriva 2012 and 2013 ($ millions)
Exhibit 29: Gilead Sciences: Revenue of Atripla 2012-2014 ($ billions)
Exhibit 30: Gilead Sciences: Revenue of Complera/Eviplera 2012-2014 ($ millions)
Exhibit 31: Gilead Sciences: Revenue of Viread 2012-2014 ($ millions)
Exhibit 32: GlaxoSmithKline: Revenue of Combivir 2012-2014 ($ millions)
Exhibit 33: GlaxoSmithKline: Revenue of Trizivir 2012-2014 ($ millions)
Exhibit 34: GlaxoSmithKline: Revenue of Agenerase and Lexiva 2012-2014 ($ millions)
Exhibit 35: GlaxoSmithKline: Revenue of Tivicay 2013-2014 ($ millions)
Exhibit 36: Johnson & Johnson: Revenue of Edurant 2012-2014 ($ millions)
Exhibit 37: Johnson & Johnson: Revenue of Prezista 2012-2014 ($ billions)
Exhibit 38: Merck: Revenue of Isentress 2012-2014 ($ billions)


【レポート販売概要】

■ タイトル:HIV治療薬の世界市場の世界市場2015-2019
■ 英文:Global HIV Drugs Market 2015-2019
■ 発行日:2015年10月14日
■ 調査会社:Technavio
■ 商品コード:IRTNTR7469
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。